BeiGene | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Beigene Study ID

BGB-A317-211

ClinicalTrials.gov ID

NCT04401800

China Drug Trials ID

CTR20200972

Sex: All

Age: 18 Years / 70 Years

No Study Documents

Sex: All

Age: 18 Years / 70 Years

No Study Documents